

# Other data source

**First published:** 12/02/2024

**Last updated:** 17/10/2024

Data source

Human

## Administrative details

### Administrative details

#### Data source ID

1000

---

#### Data source acronym

Other DS

---

#### Data source qualification

If the data source has successfully undergone a formal qualification process (e.g., from the EMA, ISO or other certifications), this should be described.

No

### Data source regions and languages

### Data source establishment

### Studies

# List of studies that have been conducted using the data source

Spanish Real World Data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (S-REAL Study)

A Prospective, Non-interventional, Long-term, Multinational Cohort Safety Study of Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (hATTR-PN) (TEG4001)

205071 - A phase IV, longitudinal, cross-sectional, retrospective, ancillary epidemiology study of the EPI-MAL-005 study to evaluate the genetic diversity in the Plasmodium falciparum parasite circumsporozoite sequences before and after the implementation of the RTS,S/AS01E vaccine in malaria-positive subjects ranging from 6 months to less than 5 years of age (EPI-MALARIA-010 VS AME)

A Prospective, Registry-based, Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant: The Migraine Observational Nurtec Pregnancy Registry (MONITOR)

SABLE: A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without Benlysta (Belimumab) (116543)

116682 - An epidemiology study to assess Plasmodium falciparum parasite prevalence and malaria control measures in catchment areas of two studies pre- and post RTS,S/AS01E introduction (EPI MAL-002 and EPI-MAL-003) to assess, in field conditions, vaccine benefit:risk in children in sub Saharan Africa. (EPI-MALARIA-005 BOD AME)

A retrospective observational chart review study to evaluate the clinical effectiveness of treatment with zanamivir 10 mg/ml solution for infusion in a cohort of intensive care unit-treated (ICU) patients with complicated influenza

infection (208165)

International Active Surveillance Study: Native Estrogen Estetrol (E4) Safety Study (INAS-NEES)

COVID-19 International Drug Pregnancy Registry (COVID-PR)

Prospective Cohort Study and Emulated Target Trial to Estimate the Safety and Effectiveness of MVA-BN vaccination against MPXV infection in at-risk individuals in Germany (SEMVAc/TEMVAc)

A prospective study to evaluate the safety, effectiveness and impact of the RTS, S/AS01E vaccine in young children in sub-Saharan Africa (EPI-MALARIA-003 VS AME) (115056)

A Multicenter, Retrospective, Observational Study Using Real-world Data to Describe the Safety, Treatment Pattern and Effectiveness of Nirmatrelvir/Ritonavir among Patients treated with Nirmatrelvir/Ritonavir in China

A propensity score-matched analysis of depersonalized 4-week data from the German Pain e-Registry on the efficacy and tolerability of quinine sulphate vs. pridinol mesylate in the prevention and treatment of painful nocturnal leg cramps (PRISCILA)

INotuzumab Treatment Retrospective Analysis for Navigating tranSITION to CD19 CAR-T. Real-world (RWD) treatment patterns and clinical outcomes in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukaemia (ALL) treated with inotuzumab-ozogamicin (InO) as bridge to chimeric antigen receptor T-cell (CAR-T) therapy in Spain, the United Kingdom (UK) and the United States (US) (INO-TRANSIT)

Real-world Comparative Effectiveness of Evolocumab Versus Ezetimibe in Reducing the Risk of Fatal and Nonfatal Myocardial Infarction (20240027)

International Active Surveillance Study: Native Estrogen Estetrol (E4) Safety Study (INAS-NEES)

Real-world post-authorization effectiveness study (PAES) of pembrolizumab for the treatment of NSCLC across races, ethnicities, and age groups (MK-3475-G18)

Real-world Study on Bemiparin Effect in Patients with Cancer-Associated Thromboembolism Using Artificial Intelligence (BEMICAT Study)

Antibiotics in primary care: impact of a Clinical Decision Support System (CDSS) in the French, Ile-de-France area - Antibioclic+

Post-marketing study to assess the risk of intussusception after immunization with GlaxoSmithKline (GSK) Biologicals' oral live-attenuated human rotavirus vaccine in infants less than 1 year old in Latin America (212329)

Evaluating the benefits of RSV maternal vaccination using a Scottish National Dataset. (BORLAND)

Effectiveness and immunogenicity of respiratory syncytial virus vaccine (RSVpreF from Pfizer) for pregnant persons: A living systematic review and meta-analysis

Real World Utilization and Effectiveness of Romosozumab Among Osteoporosis Patients in Hong Kong (20250006)

A multicentre, non-interventional, cohort analysis describing the patients' experience focusing on safety events among metastatic hormone-sensitive prostate cancer patients treated with Androgen Receptor Pathway Inhibitors (ARPIs) followed through a Telemonitoring tool funded by the French national healthcare insurance complemented with a chart review (ESPERANTO)

Discontinuation of additional risk minimisation measure tools for centrally authorised medicinal products in the EU

Real-life Enfortumab Vedotin Outcomes as First-line Urothelial Carcinoma Treatment in the Non-interventional Observational and Nationwide French Study

Enzalutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): A Non-Interventional Center-based Chart Review in Europe (ENHANCE)

An Active Surveillance, Post-Authorization Safety Study to Characterize the Safety of Etrasimod in Patients with Ulcerative Colitis Using Real-World Data in the European Union (C5041046)

Pregnancy, fetal and infant outcomes of pregnancies exposed to eptinezumab compared to two migraine control cohorts unexposed to eptinezumab: a claims database study in the United States

Oral and Long-Acting Injectable Cabotegravir Preexposure Prophylaxis Use Among U.S. Veterans Using Veterans Health Administration Services, 2021-2025 (306339)

Comparative Effectiveness of Zepbound® (tirzepatide) versus Wegovy® (semaglutide) injection and versus no OMM treatment for Cardiovascular Outcomes in People with Obesity without Diabetes

## Data elements collected

The data source contains the following information

### **Disease information**

Does the data source collect information with a focus on a specific disease? This might be a patient registry or other similar initiatives.

No

---

### **Rare diseases**

Are rare diseases captured? In the European Union a rare disease is one that affects no more than 5 people in 10,000.

No

---

### **Pregnancy and/or neonates**

Does the data source collect information on pregnant women and/or neonatal subpopulation (under 28 days of age)?

No

---

### **Hospital admission and/or discharge**

No

---

### **ICU admission**

Is information on intensive care unit admission available?

No

---

### **Cause of death**

Not Captured

---

### **Prescriptions of medicines**

Not Captured

---

### **Dispensing of medicines**

Not Captured

---

### **Advanced therapy medicinal products (ATMP)**

Is information on advanced therapy medicinal products included? A medicinal product for human use that is either a gene therapy medicinal product, a somatic cell therapy product or a tissue engineered products as defined in Regulation (EC) No 1394/2007 [Reg (EC) No 1394/2007 Art 1(1)].

No

---

### **Contraception**

Is information on the use of any type of contraception (oral, injectable, devices etc.) available?

No

---

### **Indication for use**

Does the data source capture information on the therapeutic indication for the use of medicinal products?

Not Captured

---

### **Medical devices**

Is information on medicinal devices (e.g., pens, syringes, inhalers) available?

No

---

### **Administration of vaccines**

No

---

### **Procedures**

Does the data source capture information on procedures (e.g., diagnostic tests, therapeutic, surgical interventions)?

Not Captured

---

### **Healthcare provider**

Is information on the person providing healthcare (e.g., physician, pharmacist, specialist) available?

The healthcare provider refers to individual health professionals or a health facility organisation licensed to provide health care diagnosis and treatment services including medication, surgery and medical devices.

No

---

## **Clinical measurements**

Is information on clinical measurements (e.g., BMI, blood pressure, height) available?

No

---

## **Genetic data**

Are data related to genotyping, genome sequencing available?

Not Captured

---

## **Biomarker data**

Does the data source capture biomarker information? The term “biomarker” refers to a broad subcategory of medical signs ( objective indications of medical state observed from outside the patient), which can be measured accurately and reproducibly. For example, haematological assays, infectious disease markers or metabolomic biomarkers.

Not Captured

---

## **Patient-reported outcomes**

Is information on patient-reported outcomes (e.g., quality of life) available?

No

---

## **Patient-generated data**

Is patient-generated information (e.g., from wearable devices) available?

No

---

## **Units of healthcare utilisation**

Are units of healthcare utilisation (e.g., number of visits to GP per year, number of hospital days) available or can they be derived? Units of healthcare utilisation refer to the quantification of the use of services for the purpose of preventing or curing health problems.

No

---

## **Unique identifier for persons**

Are patients uniquely identified in the data source?

No

---

## **Diagnostic codes**

Not Captured

---

## **Medicinal product information**

Not Captured

---

## **Quality of life measurements**

Not Captured

---

## **Lifestyle factors**

Not Captured

---

## **Sociodemographic information**

Not Captured

# Data flows and management

## Access and validation

### **Biospecimen access**

Are biospecimens available in the data source (e.g., tissue samples)?

No

---

### **Access to subject details**

Can individual patients/practitioners/practices included in the data source be contacted?

No

## Data source linkage

## **Linkage**

Is the data source described created by the linkage of other data sources (prelinked data source) and/or can the data source be linked to other data source on an ad-hoc basis?

No

## Data management specifications that apply for the data source

### **Possibility of data validation**

Can validity of the data in the data source be verified (e.g., access to original medical charts)?

No

---

### **Data source preservation**

Are records preserved in the data source indefinitely?

No

---

### **Approval for publication**

Is an approval needed for publishing the results of a study using the data source?

No

## Common Data Model (CDM) mapping

### **CDM mapping**

Has the data source been converted (ETL-ed) to a common data model?

No